Lung precision oncology program (lpop) | veterans affairs

LPOP and the Bay Pines VA are committed to providing Veterans access to clinical trials which can include prevention, diagnosis and even treatment. The Bay Pines VA LPOP site is active in

several cutting-edge clinical trials aimed at detecting, treating, and even preventing lung cancer in Veterans. If you would like more information or learn more about participating in one of

our many trials, click the 'plus' sign below and talk to one of our coordinators to learn more about opportunities which may be available to you.  Our focus is to provide targeted

cancer care for Veterans while facilitating access to investigational therapies through clinical trials. CLINICAL TRIAL TITLE: NIGHTINGALE (VERACYTE) CliNIcal Utility of ManaGement of

Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab ClassifiEr – with Familiarization CLINICAL TRIAL OVERVIEW: As part of the study, one nasal brushing

specimen will be collected. Your physician may use the test result as an aid in managing your lung nodule. The information obtained may also aid future patients by helping improve the

assessment of lung nodules and treatment plans. CONTACT INFORMATION: Ronald Eland BS, Study Coordinator [email protected] or BACKGROUND INFORMATION: The main goal of this research study is

to evaluate the usefulness of the Percepta Nasal Swab in determining the risk of lung cancer when a new lung nodule is detected by imaging as part of lung cancer screening or incidentally

during a medical work up. The local Principal Investigator (PI) for this clinical trial is Stephen Clum, MD, PhD. Clinical Trial Number: NCT06426628 ------------------------- CLINICAL TRIAL

TITLE: KRYSTAL-7 (Bristol Myers Squibb) A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab

versus Pembrolizumab plus Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation CLINICAL TRIAL OVERVIEW: This study will evaluate how effective these

medications are in shrinking or slowing down the growth of lung cancer tumors. It allows participants to play a more proactive role in their own health by receiving a new treatment for an

ongoing disease or condition. Participants may also play an important part in bringing much-needed drugs to market, benefiting thousands of patients who also have the disease or condition. 

CONTACT INFORMATION: Ronald Eland BS, Study Coordinator [email protected] or BACKGROUND INFORMATION: Phase 2: This study will assess the efficacy and safety of Adagrasib monotherapy and,

in combination with Pembrolizumab, as a first-line treatment in patients with Advanced Non-Small Cell Lung Cancer with a KRAS G12C mutation. Phase 3: This phase will compare the efficacy of

Adagrasib administered in combination with pembrolizumab versus pembrolizumab plus chemotherapy in patients with Advanced Non-Small Cell Lung Cancer with a KRAS G12C mutation. The local

Principal Investigator (PI) for this clinical trial is Ryan Burri, MD. Clinical Trial Number: NCT04613596 ------------------------- CLINICAL TRIAL TITLE: VA VALOR (VA-CSP) Veterans Affairs

Lung Cancer Surgery Or Stereotactic Radiotherapy Trial CLINICAL TRIAL OVERVIEW: The VA is doing everything it can to improve the manner in which we treat lung cancer, and improve patient

outcomes for patients who have stage one lung cancer. Veterans diagnosed with stage I non-small cell lung cancer who are healthy enough to have surgery, agree to be randomized to either

surgery (standard of care treatment) or an alternative non-surgical treatment - Stereotactic Radiotherapy (SBRT).  The data you provide will help understand the effectiveness and outcomes of

the treatments. The knowledge gained from this study will be used in the future by doctors to guide Stage I lung cancer treatment for Veterans and other patients.  CONTACT INFORMATION: 

Marlene Kern, DNP, RN, Study Coordinator [email protected] or 727-398-6661, ext. 13917 BACKGROUND INFORMATION: SBRT uses very precisely targeted radiation to destroy the cancer in the

lung. However, there has not been a study comparing SBRT and Surgery in patients who are physically fit and suitable for both treatments. Therefore, this study is being done to compare

Surgery and SBRT directly. There is evidence that some patients feel better supported during research studies, and some report better outcomes. The local PIs for this clinical trial are Ryan

Burri, MD, and Edward Hong, MD. Clinical Trial Number: NCT02984761 ------------------------- CLINICAL TRIAL TITLE: ARTEMiDE Lung-02 (Astra Zeneca) Phase III, Randomized, Double Blind, Multi

Center, Global Study of Rilvegostomig in Combination with Platinum-based Chemotherapy for the First-line treatment of patients with Metastatic Squamous Non- Small Cell Lung Cancer.

(ARTEMiDE LUNG-02) CLINICAL TRIAL OVERVIEW: The main goal of this research study is to demonstrate and characterize the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab

plus chemotherapy by assessment of overall survival. CONTACT INFORMATION: Ronald Eland BS, Study Coordinator [email protected] or BACKGROUND INFORMATION: The purpose of ARTEMIDE-Lung03 is

to assess the efficacy and safety of rilvegostomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with squamous

metastatic NSCLC and whose tumors express PD-L1 (TC ≥ 1%). This study will be conducted in approximately 350 sites across 25 to 30 countries. Participants must have tumors that lack

epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements; in addition, tumors must not have any documented actionable

genomic mutations identified by local standard practice for which there are locally approved first-line targeted therapies. The local Principal Investigator (PI) for this clinical trial is

Harsh Bhushan, MD. Clinical Trial Number: TBA ------------------------- CLINICAL TRIAL TITLE: ARTEMiDE Lung-03 (Astra Zeneca) A Phase III, Randomized, Double-Blind, Multicenter, Global Study

of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC) (ARTEMiDE LUNG-03) CLINICAL TRIAL

OVERVIEW: The main goal of this research study is to demonstrate and characterize the efficacy of rilvegostomig plus chemotherapy relative to pembrolizumab plus chemotherapy by assessment of

overall survival in patients with metastatic Non-squamous Non-Small Cell Lung Cancer (NSCLC). CONTACT INFORMATION: Ronald Eland BS, Study Coordinator [email protected] or BACKGROUND

INFORMATION: The purpose of ARTEMIDE-Lung03 is to assess the efficacy and safety of rilvegostomig in combination with chemotherapy compared with pembrolizumab in combination with

chemotherapy as 1L treatment in participants with non-squamous metastatic NSCLC and whose tumors express PD-L1 (TC ≥ 1%). This study will be conducted in approximately 350 sites across 25 to

30 countries. Participants must have tumors that lack epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements; in

addition, tumors must not have any documented actionable genomic mutations identified by local standard practice for which there are locally approved first-line targeted therapies. The local

Principal Investigator (PI) for this clinical trial is Harsh Bhushan, MD. Clinical Trial Number: TBA